Mohammad-Reza Shalbafan
Overview
Explore the profile of Mohammad-Reza Shalbafan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
74
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khalaj M, Saghazadeh A, Shirazi E, Shalbafan M, Alavi K, Shooshtari M, et al.
J Psychiatr Res
. 2018 May;
103:104-111.
PMID: 29807317
Inflammation as well as glutamate excitotoxicity have been proposed to participate in the propagation of autism. Palmitoylethanolamide (PEA) is an endocannabinoid proven to prevent glutamatergic toxicity and inhibit inflammatory responses...
2.
Ghazizadeh-Hashemi M, Ghajar A, Shalbafan M, Ghazizadeh-Hashemi F, Afarideh M, Malekpour F, et al.
J Affect Disord
. 2018 Feb;
232:127-133.
PMID: 29486338
Background: Experimental studies provide evidence for antidepressant effects of Palmitoylethanolamide (PEA) in animal models of depression. We aimed to evaluate the efficacy and tolerability of PEA add-on therapy in treatment...
3.
Ghajar A, Khoaie-Ardakani M, Shahmoradi Z, Alavi A, Afarideh M, Shalbafan M, et al.
Psychiatry Res
. 2018 Feb;
262:94-101.
PMID: 29427913
Since l-carnosine has shown effectiveness in improvement of cognition in patients with schizophrenia, this 8-week, randomized, double-blind, placebo-controlled pilot study was conducted. Sixty-three patients with chronic schizophrenia, who were clinically...
4.
Esalatmanesh S, Abrishami Z, Zeinoddini A, Rahiminejad F, Sadeghi M, Najarzadegan M, et al.
Psychiatry Clin Neurosci
. 2016 Aug;
70(11):517-526.
PMID: 27488081
Aim: Several lines of evidence implicate glutamatergic dysfunction in the pathophysiology of obsessive-compulsive disorder (OCD), presenting this neurotransmitter as a target for the development of novel pharmacotherapy. The objective of...